RANI

$1.31

Market ClosedAs of Mar 17, 8:00 PM UTC

Rani Therapeutics Holdings, Inc.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

TipRanks
Jan 24, 2026

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 105.13% +2.83, GraniteShares 1.5x Long COIN Daily ETF (CONL) 11.48% +0.83, Icici Bank (IBN) 1.10% +0.80, EETH ETF (EETH) 19.93% +0.59, Tradr 2X Long IREN Daily ETF (IREX) 24.34% +0.56, iShares Investment Grade Corporate Bond ETF (LQD) 3.00% +0.55, Beyond Meat (BYND) 12.97% +0.49, Rani Therapeutics Holdings (RANI) 18.04% +0.44, Direxion Daily 20 plus Year Treasury Bear

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 23, 2026

Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%

Key Insights Rani Therapeutics Holdings' significant retail investors ownership suggests that the key decisions are...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Oct 26, 2025

H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential

Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes that the company has 3 major value drivers: the platform technology RaniPill, a recent […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Yahoo Finance UK
Oct 20, 2025

Trending tickers: Apple, Beyond Meat, Rani Therapeutics, BitMine and B&M

The latest investor updates on stocks that are trending on Monday.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Oct 20, 2025

Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost

Rani Therapeutics Holdings (RANI) has grabbed attention after announcing a collaboration and license agreement with Chugai Pharmaceutical for an oral rare disease therapy. The deal includes payments tied to development milestones as well as future product commercialization. See our latest analysis for Rani Therapeutics Holdings. Rani Therapeutics’ share price has skyrocketed over 240% in the past month following its blockbuster deal with Chugai and a $60 million financing round, demonstrating...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.